CN109320473A - Thiazole aminobenzamide acetic acid derivatives and their uses - Google Patents

Thiazole aminobenzamide acetic acid derivatives and their uses Download PDF

Info

Publication number
CN109320473A
CN109320473A CN201811209798.5A CN201811209798A CN109320473A CN 109320473 A CN109320473 A CN 109320473A CN 201811209798 A CN201811209798 A CN 201811209798A CN 109320473 A CN109320473 A CN 109320473A
Authority
CN
China
Prior art keywords
reaction
alkyl
compound
add
solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201811209798.5A
Other languages
Chinese (zh)
Other versions
CN109320473B (en
Inventor
彭俊梅
刘娟
曹轩
黄红林
贺冬秀
谢志忠
喻翠云
李娜
罗景顺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of South China
Original Assignee
University of South China
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of South China filed Critical University of South China
Priority to CN201811209798.5A priority Critical patent/CN109320473B/en
Publication of CN109320473A publication Critical patent/CN109320473A/en
Application granted granted Critical
Publication of CN109320473B publication Critical patent/CN109320473B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开了一种具备抗肿瘤活性的噻唑氨基苯甲酰胺乙酸衍生物，其能够用于制备抗癌药物，特别是作为Bcr‑Abl酪氨酸激酶抑制剂，尤其是可作为T315I突变的Bcr‑Abl酪氨酸激酶抑制剂。The invention discloses a thiazole aminobenzamide acetic acid derivative with antitumor activity, which can be used for preparing anticancer drugs, especially as a Bcr-Abl tyrosine kinase inhibitor, especially as a T315I mutant Bcr ‑Abl tyrosine kinase inhibitor.

Description

Thiazoleamino benzamide acetogenin and application thereof
Technical field
The present invention relates to field of medicinal chemistry, and in particular to a series of thiazoleamino benzamide acetogenins, its system Preparation Method and application thereof.
Background technique
Chronic myelocytic leukemia (CML) is a kind of pernicious bone marrow proliferative diseases originating from candidate stem cell, accounts for institute There is the 15% ~ 20% of leukaemia, is the most common bone marrow proliferative diseases.Its former cancer of root on No. 9 chromosomes of falling ill The Bcr-Abl gene that Bcr Gene Fusion on gene c-Abl and No. 22 chromosomes is formed.At present, it was verified that Bcr-Abl Tyrosine kinase is treatment CML optimal molecular target (Blood, 1996,87:3036-3038；Blood, 2000, 96:343-356).Around Bcr-Abl tyrosine kinase, drug workers have carried out various effort.Currently, successfully listing Bcr-Abl tyrosine kinase inhibitor have Imatinib, nilotinib, draw mostly for Buddhist nun, Dasatinib, Shu Bo for Buddhist nun and Pu Na For Buddhist nun.
Wherein, Imatinib is first generation Bcr-Abl tyrosine kinase inhibitor, for the first-line drug for treating CML, but not Patient of the same period understands some and generates drug resistance after long-term use.Drug resistance may be caused by number of mechanisms, wherein Bcr- Abl point mutation is most common be also influence maximum resistance mechanism (Nat Rev Drug Discov, 2007,6 (10): 834-848).
Nilotinib draws and replaces Buddhist nun, Dasatinib and bosutinib for second generation Bcr-Abl tyrosine kinase inhibitor more. Compared with Imatinib, it is able to solve the drug resistance that most of mutant generate, but do not can effectively solve caused by T315I mutation Drug resistance (Ann Oncol, 2007,18 (6): 42-46； Eur J Cancer, 2010, 46 (10): 1781-1789； Haematologica, 2014,99 (7): 1191-1196).
Ponatinib is third generation Bcr-Abl tyrosine kinase inhibitor, be can effectively solve the problem that resistance to caused by T315I mutation Medicine (Cancer Cell, 2009,16 (5): 401-412).But Ponatinib can generate serious and lethal thrombus and blood vessel Stenosis disease, and complication (the Chinese drugs such as heart disease, myocardial infarction, apoplexy, limb ischemia even tissue necrosis can be induced Warning, 2017,14 (4): 218-221).
T315I mutation occurs 315 that are referred to as " gatekeeper " in Bcr-Abl kinase domain, wild type Threonine (Thr) in Bcr-Abl is replaced by isoleucine (Ile).Thr315 can be replaced with her horse in wild type Bcr-Abl Buddhist nun and nilotinib etc. form a crucial hydrogen bond, and after it is replaced by Ile315, this crucial hydrogen bond just can not shape At.In addition to this, Ile315 after being mutated since volume is larger, can and Imatinib generate steric hindrance, to keep its right Wild type Bcr-Abl is effectively and to Bcr-AblT315I invalid (Cancer Cell, 2002,2 (2): 117-125； Bioorg Med Chem Lett, 2008, 18: 4907-4912；Leukemia, 2004,18 (8): 1321-1331). The effect for studying Ponatinib and Bcr-AblT315I is found: acetylene bond and Thr315 and Ile315 in Ponatinib structure are not Hydrogen bond is formed, and (pharmacy is in progress, 2014,38 (5): 333- without generating steric hindrance with Ile315 since structure is smaller 339；Cancer Cell, 2009,16 (5): 401-412).
The present inventor designs in previous work, has synthesized serial thiazolamine class compound, active testing The result shows that its with good anti-tumor activity (CN102319244A, CN102675303, CN1080031152A, CN107459513A).Thus inventor expects for thiazolamine group being integrated in molecular structure, it is desirable to which accessing can make For the Bcr-Abl tyrosine kinase inhibitor of T315I mutation, while the toxic side effect to human body can reduce.
Summary of the invention
The technical problems to be solved by the present invention are: a kind of thiazoleamino benzamide acetogenin is provided, it can Bcr-Abl tyrosine kinase inhibitor as T315I mutation.
The first aspect of the invention is to provide a kind of compound of Formula I and its pharmaceutically acceptable salt, has as follows Structure:
I
Wherein: R1It is each independently selected from halogen ,-OH ,-NO2、-CN、C1-C6Alkyl, C1-C6Alkoxy, C1-C6Halogenated alkyl, C1-C6Halogenated alkoxy；
R2Selected from hydrogen, C1-C6Alkyl, C1-C6Alkoxy, C1-C6Halogenated alkyl, C1-C6Halogenated alkoxy；
R3Selected from hydrogen ,-OH ,-NO2,-CN, halogen, C1-C6Alkyl, C1-C6Alkoxy, C1-C6Halogenated alkyl, C1-C6Haloalkoxy Base, C6-C10Aryl C1-C6Alkyl；
N is selected from 0,1,2,3 or 4.
Preferably, R1It is each independently selected from halogen ,-OH, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 halogenated alkyl, More preferably methyl, chlorine, fluorine, hydroxyl, trifluoromethyl；N is selected from 0,1 or 2, preferably 0 or 1.
Preferably, R2Selected from hydrogen, C1-C4 alkyl, C1-C4 halogenated alkyl, more preferably methyl, ethyl, trifluoromethyl.
Preferably, R3Selected from hydrogen ,-OH, halogen, C1-C4Alkyl, C1-C6Alkoxy, C1-C4Halogenated alkyl, C1-C4Alkyl halide Oxygroup, benzyl, more preferably hydrogen, benzyl.
It is highly preferred that compound of formula I of the present invention, is selected from following compound:
。
Another aspect of the present invention provides a kind of the method for preparing compound of formula I, and reaction route is as follows:
；
Wherein, R1、R2、R3Defined as described above with n, R4 is selected from C1-C6Alkyl or C1-C6Halogenated alkyl.
Preparation method of the invention specifically further includes following reaction step:
Step 1: ammonium thiocyanate and acetone are added into reactor, stirs evenly, chlorobenzoyl chloride is then added dropwise, solution is by clarifying Become white opacity liquid, be heated to flowing back, gavaculine is added portionwise, to which after completion of the reaction, cooling is filtered, by gained Solid is dry, obtains 3-(3- benzoylthioureas base) benzoic acid；
Step 2: 3-(3- benzoylthioureas base is added into reaction flask) benzoic acid and alkaline aqueous solution, make pH=13, stirs, It is heated to reflux, until end of reaction, is cooled to room temperature, dilute hydrochloric acid is added, pH is transferred to 2, stands 24 h, solid is precipitated, is filtered, Solid is dry, obtain 3- carboxyl phenyl thiocarbamide；
Step 3: 3- carboxyl phenyl thiocarbamide, substituted 2-Br-1- phenyl alkyl ketone and glacial acetic acid, stirring are added into reaction flask Uniformly, it is heated to flowing back, after completion of the reaction, removes the insoluble solids in reaction flask while hot, rotate partial solvent, be put into ventilating kitchen Solid is precipitated in middle 24 h of room temperature cooling, and filtering is dry by obtained solid, obtains intermediate thiazoleamino benzoic acid derivative；
Step 4: intermediate thiazoleamino benzoic acid derivative, EDCI, HOBT and dehydrated alcohol are added under condition of ice bath to anti- It answers in bottle, reacts 2-4 h, be addedHydrochloride, DIPEA, DMAP and DMF continue ice bath and react half an hour, it After be changed to react at room temperature, until end of reaction, then be slowly added to ice water while stirring, until solution becomes muddy from clarifying, room Temperature stirring 0.5-1.5 h places into refrigerator and white solid is precipitated, and filtering is dry by obtained solid, obtains compound of formula I；
Step 5: intermediate 4, dehydrated alcohol and distilled water being added into reaction flask, adjust pH most 11-13 with dilute NaOH, and 37 DEG C stirring, reaction process monitor pH, be adjusted to 11-13 in time when lower than 10.TLC monitors reaction process, after completion of the reaction, filtering, Filter residue is abandoned, filtrate is 2-3 with dilute HCl tune pH, is put into refrigerator and solid, filtering, dry compound of formula I is precipitated.
Preferably, the molar ratio of the gavaculine, ammonium thiocyanate and chlorobenzoyl chloride of step 1 is 1: 1-1.5: 1-1.5, preferably 1: 1.2: 1.3；
Preferably, step 2 alkaline aqueous solution is 10% NaOH aqueous solution, and dilute hydrochloric acid concentration is 4 mol/L；
Preferably, the molar ratio of the 3- carboxyl phenyl thiocarbamide of step 3 and substituted 2-Br-1- phenyl alkyl ketone is 1: 1- 1.2, preferably 1: 1；
Preferably, in step 4WithMolar ratio be 1-2: 1, preferably 1.5: 1；
Preferably, the pH in step 5 in reaction process is preferably 12, and the pH in last handling process is preferably 2-3, and dilute NaOH is The NaOH aqueous solution of 5%-30%, dilute HCl are the hydrochloric acid solution of 5%-15%.
Another aspect of the present invention provides a kind of pharmaceutical composition, it includes compound shown in Formulas I of the present invention or Its pharmaceutically acceptable salt and pharmaceutically acceptable carrier, excipient.
Another aspect of the present invention is related to compound of the present invention or the pharmaceutical composition comprising the compound is being made Standby treatment and the purposes in the drug of Bcr-Abl tyrosine kinase associated cancer, in particular for the Bcr- of T315I mutation Abl tyrosine kinase is the cancer of target spot.
Preferably, the cancer is selected from human chronic myelogenous leukemia, liver cancer (such as HepG-2 cell strain), non-small cell lung Cancer (such as A549 cell strain) is more preferably people's chronic myelogenous leukemia (such as K562 cell strain), the K562 cell strain of resistance to Imatinib (K562/R cell strain).
Definition:
" alkyl ", which refers to, to be only made of carbon and hydrogen atom, is not contained degree of unsaturation, can is C1-6 alkyl.In some embodiments In, alkyl has 1 to 6 or 1 to 4 carbon atom.Representative straight chain saturated alkyl includes but is not limited to-methyl ,-ethyl ,-positive third Base ,-normal-butyl ,-n-pentyl and-n-hexyl；And being saturated branched alkyl includes but is not limited to-isopropyl ,-sec-butyl ,-isobutyl Base ,-tert-butyl ,-isopentyl, 2- methyl butyl, 3- methyl butyl, 2- Methyl pentyl, 3- methyl amyl, 4- methyl amyl, 2- Methylhexyl, 3- methylhexyl, 4- methylhexyl, 5- methylhexyl, 2,3- dimethyl-butyl etc..Alkyl is connected by singly-bound In parent molecule.Unless in addition statement in the description, otherwise alkyl is optionally independently taken including below by one or more Replace for base: acyl group, alkyl, alkenyl, alkynyl, alkoxy, alkylaryl, naphthenic base.In a non-limiting embodiments, take The alkyl in generation can be selected from methyl fluoride, difluoromethyl, trifluoromethyl, 2- fluoro ethyl, 3- fluoropropyl, hydroxymethyl, 2- hydroxyethyl, 3- hydroxypropyl, benzyl and phenethyl.
" alkoxy " refers to that " alkyl " is connected by oxygen atom with parent molecule, determines as described above wherein " alkyl " has Justice.
" halogenated alkyl " refers to wherein all hydrogen moieties or all by selected from fluoro base, chloro base, bromo base and iodine The alkyl of the halogen displacement of Dai Ji.In some embodiments, all hydrogen atoms are all respectively replaced by fluoro base.In some implementations In scheme, all hydrogen atoms are all respectively replaced by chloro base.The example of halogenated alkyl include-CF3 ,-CF2CF3 ,- CF2CF2CF3 ,-CFCl2 ,-CF2Cl etc..
In certain embodiments, pharmaceutically acceptable form is pharmaceutically acceptable salt, pharmaceutically acceptable Salt is well known in the art.The example of pharmaceutically acceptable salt is such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, high chlorine Acid, acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid, acetic acid, propionic acid, glycolic, pyruvic acid, Oxalic acid, lactic acid, trifluoroacetic acid, Loprazolam, ethane sulfonic acid, p-methyl benzenesulfonic acid, salicylic acid etc..
" pharmaceutically acceptable carrier " or " pharmaceutically acceptable excipient " includes any and all solvents, dispersion Jie Matter, covering, isotonic agent and absorption delaying agent etc..Pharmaceutically acceptable carrier or excipient do not destroy disclosed compound Pharmacological activity, and be nontoxic when to be enough to deliver the dosage application of the compound of therapeutic dose.Pharmaceutically active substance The use of the medium and reagent is in the art well known.
Compared with prior art, the beneficial effects of the present invention are:
(1) the present invention provides a new class of thiazoleamino benzamide phenylacetic acid compound with anticancer activity, is widened The range of existing anticancer compound can be used as lead compound and continue to optimize；
(2) the compounds of this invention is to CML cell cycling inhibiting, the K562 cell of resistance to Imatinib (K562/R), human liver cancer cell (HepG-2) and Non-small cell lung carcinoma cell (A549) has good inhibiting effect, has simultaneously for human normal liver cell L 02 There is lower toxicity, while inhibiting cancer cell, can be avoided or reduce the toxic side effect to human body；
(3) the compounds of this invention can be with target tyrosine kinase A bI1 and AbIlT315IIt is effectively combined, has and make well With intensity, it is able to suppress Bcr-AbIlT315IActivity, and then efficiently solve T315I be mutated caused by resistance problems, can be used as The novel B cr-Abl tyrosine kinase inhibitor of anti-T315I mutation.
Specific embodiment
The contents of the present invention are illustrated below by embodiment.In the present invention, following embodiment is in order to more preferable Ground illustrates the present invention, is not for limiting the scope of the invention.Material used in embodiment, reagent etc., such as without special theory It is bright, it is commercially available.
Embodiment 1(3- ((5- methyl 4-phenyl thiazol-2-yl) amino) benzoyl) glycine
Step a:
11.4341 g(0.12 mol are added in angle reaction flask of 100 mL with mechanical stirring and condenser pipe) ammonium thiocyanate With 20 mL acetone, stirred evenly by mechanical stirring.16.8034 g(0.13 mol are added dropwise) chlorobenzoyl chloride (10 min are dripped off), Solution becomes white opacity liquid from clarifying.It is heated to flowing back, point 4 crowdes of 14.1147 g(0.10 mol of addition) gavaculine, TLC(ethyl acetate: petroleum ether=4:1) monitoring reaction course, 8 h end of reaction.Cooling, filtering is dry by obtained solid, Obtain the pale yellow powder 3-(3- benzoylthioureas base of 28.0041 g) benzoic acid, 184 ~ 186 DEG C of m.p..
0.9913 g(0.12 mol is added in angle reaction flask of 100 mL with condenser pipe) 3-(3- benzoylthioureas Base) 10% NaOH of benzoic acid and 33 mL, pH=13 are measured, magnetic agitation is heated to reflux, TLC(ethyl acetate: petroleum ether= 4:1) monitor its reaction process, 4 h end of reaction.It is cooled to room temperature, suitable 4 mol/L dilute hydrochloric acid is added, pH is transferred to 2, Stand 24 h, solid be precipitated, filtering is dry by obtained solid, weigh 0.6142 g white powder, yield is 86.72 %, m.p. 186 ~ 187 ℃。 1H NMR(DMSO-D6, 400 MHz),δ: 2.51(s, 1H, NH), 3.36(s, 2H, NH2), 7.43-8.03(m 4H, C6H4), 9.89(s, 1H, COOH).
Step b:3- [(5- ethyl -4- phenyl thiazole -2- base) amino] benzoic acid
3.9432 g(0.02 mol are added in angle reaction flask of 100 mL with condenser pipe) 3- carboxyl phenyl thiocarbamide, 4.5213 G(0.02mol) 2-Br-1- phenyl butanone and 20mL glacial acetic acid, stir evenly, and are heated to flowing back, TLC (solvent: acetic acid second Ester: petroleum ether=4:1) monitoring reaction process, reacts about 24 h.The insoluble solids in reaction flask are removed while hot, rotate part Solvent.It is put into 24 h of room temperature cooling in ventilating kitchen, solid is precipitated, filtering is dry by obtained solid, weighs to obtain 5.6.163 g Brownish-yellow powder, yield are 66.54 %, m.p.229 ~ 231 DEG C.1H NMR(DMSO-D6, 400 MHz),δ: 1.25(t, 3H,J=8.0 Hz, CH3), 2.85(q, 2H,J=8.0 Hz, CH2), 7.32-8.27(m, 9H, C6H4, C6H5), 10.38(s, 1H, COOH).
Step c:(3- ((5- methyl 4-phenyl thiazol-2-yl) amino) benzoyl) glycine methyl ester
0.4153g(0.003mol is added under condition of ice bath) 3-[(5- ethyl-4- phenyl thiazole-2- base) amino] benzoic acid, 0.5812g(0.003mol) EDCI, 0.4154g(0.003mol) HOBT and 18ml dehydrated alcohol to three-necked flask, reacts about 3h Afterwards, be added 0.2502g(0.002mol) glycine methyl ester hydrochloride, 0.8ml DIPEA, 0.0979g(0.0008mol) DMAP and 18mlDMF continues ice bath and reacts half an hour, is changed to react at room temperature later, TLC(ethyl acetate: petroleum ether=4:1) monitoring reaction Process, about 21 hours end of reaction.It is slowly added to ice water while stirring, until solution becomes muddiness, about 40ml, room from clarifying Temperature stirring 30min, places into refrigerator and white solid is precipitated.Filtering, obtained solid is dry, the white powder of 0.2112 g is obtained, m.p. 135 ~ 137℃。1H NMR(CDCl3, 400 MHz),δ: 1.30(t,J =8.0 Hz, 3H, CH2CH3), 1.41(s, 3H, OCH3), 2.89(q,J=8.0 Hz, 2H, CH2CH3), 4.39(d,J=4.0 Hz, 2H, NHCH2), 7.26-8.00(m, 9H, C6H5, C6H4).
Step d:(3- ((5- methyl 4-phenyl thiazol-2-yl) amino) benzoyl) glycine
(3- ((5- methyl 4-phenyl thiazol-2-yl) amino) benzoyl) glycine methyl ester is added in 50ml three-necked flask 0.1532g(0.4mmol), 15ml dehydrated alcohol and 3ml distilled water, adjusting pH with dilute NaOH is about 12,37 DEG C of stirrings, is reacted Range monitoring pH is adjusted to 12 when lower than 10 in time.TLC (solvent: ethyl acetate: petroleum ether=1:1) monitors reaction process, React about 2h.After completion of the reaction, it filters, abandons filter residue, filtrate is 2-3 with dilute HCl tune Ph, is put into refrigerator and solid is precipitated, filter, do It is dry to obtain 0.0865g yellow powder, yield 56.78 %, m.p. 200-202- DEG C.1H NMR(DMSO-D6, 400 MHz),δ: 1.22 (t,J =8.0 Hz, 3H, CH2CH3), 2.82(q,J=8.0 Hz, 2H, CH2CH3), 3.93(d,J=4.0 Hz, 2H, NHCH2), 7.37-8.07(m, 9H, C6H4, C6H5), 8.87(t,J =4.0 Hz, 1H, CONH), 10.79(s, 1H, COOH).
Embodiment 2 (3- ((5- methyl -4- (p-methylphenyl) thiazol-2-yl) amino) benzoyl) glycine
Operation is same as above, and obtains the brown powder of 0.0934g, yield 61.28%, and m.p.225-228 DEG C.1H NMR(DMSO-D6, 400 MHz),δ: 2.36(s, 3H, CH3), 2.41(s, 3H, CH3), 3.93(d,J=8.0 Hz, 2H, NHCH2), 7.26-8.08(m, 8H, 2 × C6H4), 8.82(t,J=8.0 Hz, 1H, CONH), 10.49(s, 1H, COOH).
3 3- of embodiment ((4- (4- chlorphenyl) -5- methylthiazol -2- base) amino) benzoyl) glycine
Operation is same as above, and obtains the yellow powder of 0.09492g, yield 59.18%, and m.p.238-240 DEG C.1H NMR(DMSO-D6, 400 MHz),δ: 2.43(s, 3H, CH3), 3.91(d,J=8.0 Hz, 2H, NHCH2), 7.26-8.08(m, 8H, 2 × C6H4), 8.75 (t,J=8.0 Hz, 1H, CONH), 10.25(s, 1H, COOH).
Embodiment 4 (3-((4-(4- chlorphenyl) -5- ethyl thiazole -2- base) amino) benzoyl) glycine
Operation is same as above, and obtains the yellow powder of 0.1194g, yield 71.86%, and m.p161-163. DEG C.1H NMR(CDCl3, 400 MHz),δ: 1.28(t,J =8.0 Hz, 3H, CH2CH3), 2.18(q,J=8.0 Hz, 2H, CH2CH3), 4.26(d,J = 8.0 Hz, 2H, NHCH2), 6.95-7.79(m, 9H, 2 × C6H4).
Embodiment 5 (3- ((4- (4- hydroxy phenyl) -5- methylthiazol -2- base) amino) benzoyl) glycine
Operation is same as above, and obtains the yellow powder of 0.0772g, yield 50.36%, and m.p.194-197 DEG C.1H NMR(DMSO-D6, 400 MHz),δ: 2.43(s, 3H, CH3), 3.93(d,J=8.0 Hz, 2H, NHCH2), 7.26-8.08(m, 8H, 2 × C6H4), 8.75 (t,J=8.0 Hz, 1H, CONH), 10.25(s, 1H, COOH).
Embodiment 6 (3-((4-(4- fluorophenyl) -5- methylthiazol -2- base) amino) benzoyl) glycine
Operation is same as above, and obtains the shallow green powder of 0.1528g, yield 80.59%, and m.p.211-213 DEG C.1H NMR(DMSO-D6, 400 MHz),δ: 2.43(s, 3H, CH3), 3.93(d,J=8.0 Hz, 2H, NHCH2), 7.26-8.08(m, 8H, 2 × C6H4), 8.75(tJ=8.0 Hz, 1H, CONH), 10.25(s, 1H, COOH).
Embodiment 7 (3-((5- methyl 4-phenyl thiazol-2-yl) amino) benzoyl) glycine
Operation is same as above, and obtains 0.0962g yellow powder, yield 81.29 %, m.p.283-285 DEG C.1H NMR(DMSO-D6, 400 MHz),δ: 2.44(s, 3H, CH3), 3.93(d,J=8.0 Hz, 2H, NHCH2), 7.69-8.05(m, 9H, C6H4, C6H5), 8.77(tJ=8.0 Hz, 1H, CONH), 10.24(s, 1H, COOH).
Embodiment 8 (3- ((5- methyl -4- (4- (trifluoromethyl) phenyl) thiazol-2-yl) amino) benzoyl) sweet ammonia Acid
Operation is same as above, and obtains 0.1349g yellow powder, yield 81.29 %, m.p.183-186 DEG C.1H NMR(DMSO-D6, 400 MHz),δ: 2.45(s, 3H, CH3), 3.95(d,J=8.0 Hz, 2H, NHCH2), 7.29-8.10(m, 8H, 2 × C6H4), 8.78 (t,J=8.0 Hz, 1H, CONH), 10.27(s, 1H, COOH).
Embodiment 9(3-((5- ethyl-4- phenyl thiazole-2- base) amino) benzoyl) phenylalanine
Operation is same as above, and obtains 0.1182g white powder, yield 62.74%, m.p.199-202 DEG C.1H NMR(DMSO-D6, 400 MHz),δ: 1.24(t,J =8.0 Hz, 3H, CH2CH3) 2.84(q,J=8.0 Hz, 2H, CH2CH3), 3.18(m, 2H, CH2C6H5), 4.63 (m, 1H, CH), 7.16-7.97(m, 14H, 2 × C6H5, C6H4), 8.66(d,J=8.0 Hz, 1H, CONH), 10.27(s, 1H, COOH).
Embodiment 10(3-((5- methyl -4-(p-methylphenyl) thiazol-2-yl) amino) benzoyl) phenylalanine
Operation is same as above, and obtains 0.1183g white powder, yield 62.79%, m.p.223-225 DEG C.1H NMR(DMSO-D6, 400 MHz),δ: 2.37(s, 3H, CH3), 2.45(s, 3H, CH3), 3.10(m, 2H, CH2C6H5), 4.65 (m, 1H, CH), 7.07-7.98 (m, 13H, 2 × C6H4, C6H5), 8.66(d,J =8.0,1H, CONH), 10.21(s, 1H, COOH).
Embodiment 11(3-((4-(4- chlorphenyl) -5- methylthiazol -2- base) amino) benzoyl) phenylalanine
Operation is same as above, and obtains 0.1401g white powder, yield 71.34%, m.p.237-239 DEG C.1H NMR(DMSO-D6, 400 MHz),δ: 2.50(s, 3H, CH3), 3.8(m, 2H, CH2C6H5), 4.62 (m, 1H, CH), 7.17-7.95(m, 13H, 2 × C6H4, C6H5), 8.65(d,J =8.0,1H, CONH), 10.29(s, 1H, COOH).
Embodiment 12(3-((4-(4- chlorphenyl)-5- ethyl thiazole-2- base) amino) benzoyl) phenylalanine
Operation is same as above, and obtains 0.1280g white powder, yield 66.03%, m.p192-194. DEG C.1H NMR(DMSO-D6, 400 MHz),δ: 1.23(t,J =8.0 Hz, 3H, CH2CH3) 2.84(q,J=8.0 Hz, 2H, CH2CH3), 3.07(m, 2H, CH2C6H5), 4.13 (m, 1H, CH), 7.19-7.92(m, 13H, 2 × C6H4, C6H5), 7.98(s, 1H, CONH), 10.59(s, 1H, COOH).
Embodiment 13 (3- ((4- (4- hydroxy phenyl) -5- methylthiazol -2- base) amino) benzoyl) phenylalanine
Operation is same as above, and obtains 0.1048g white powder, yield 55.37%, m.p.156-158 DEG C.1H NMR(DMSO-D6, 400 MHz),δ: 2.39(3,3H, CH3), 3.11(m, 2H, CH2C6H5), 4.62 (m, 1H, CH), 6.83-7.94(m, 13H, 2 × C6H4, C6H5), 8.65(d,J =8.0,1H, CONH), 10.18(s, 1H, COOH).
Embodiment 14(3-((4-(4- fluorophenyl)-5- methylthiazol-2- base) amino) benzoyl) phenylalanine
Operation is same as above, and obtains 0.1289g white powder, yield 67.82%, m.p.228-130 DEG C.1H NMR(DMSO-D6, 400 MHz),δ: 2.45(s, 3H, CH3), 3.11(m, 2H, CH2C6H5), 4.62 (m, 1H, CH), 7.20-7.96(m, 13H, 2 × C6H4, C6H5), 8.65(d,J =8.0,1H, CONH), 10.24(s, 1H, COOH).
Embodiment 15(3-((5- methyl 4-phenyl thiazol-2-yl) amino) benzoyl) phenylalanine
Operation is same as above, and obtains 0.1190g white powder, yield 63.18%, m.p.207-210 DEG C.1H NMR(DMSO-D6, 400 MHz),δ: 2.47(3,3H, CH3), 3.11(m, 2H, CH2C6H5), 4.62 (m, 1H, CH), 7.20-7.98(m, 14H, 2 × C6H5, C6H4), 8.65(d,J =8.0,1H, CONH), 10.26(s, 1H, COOH).
Embodiment 16 (3- ((5- methyl -4- (4- (trifluoromethyl) phenyl) thiazol-2-yl) amino) benzoyl) phenylpropyl alcohol Propylhomoserin
Operation is same as above, and obtains 0.1586g white powder, yield 56.47%, m.p.193-196 DEG C.1H NMR(DMSO-D6, 400 MHz),δ: 2.46(s, 3H, CH3), 3.08(m, 2H, CH2C6H5), 4.62 (m, 1H, CH), 7.17-8.66(m, 13H, 2 × C6H4, C6H5), 8.65(d,J =8.0,1H, CONH), 10.21(s, 1H, COOH).
17 compound of embodiment and target tyrosine kinase A bl (PDB:2GQG) and Bcr-AblT315I(PDB:3IK3) into Row docking marking
Using molecular simulation software sybyl to the compound and target Bcr-Abl of designed synthesisT315I(PDB:3IK3) it carries out Docking.Docking intensity is stronger, and it is better for the inhibitory effect of target kinases to show.Following (the specific behaviour of each step of testing procedure Work can be configured according to software requirement):
2.1 obtain albumen
Log in network address http://www.rcsb.org/pdb/home/home.do downloading albumen (PDB:3IK3)；By quasi- testization Object is closed to be stored in it in SLN file with mol2 format with chemdream 3D pro.
2.2 import the albumen that albumen imports quasi- docking according to software operating method.
2.3 protein prepare
2.4 analysis protein structures simultaneously prepare to dock
Other settings of 2.5 detections
The 2.6 specified ligands to be docked and submission work
The result of 2.7 browsing Surflex-Dock
After terminating all interaction docking operations, marking result can be popped up actively in Results Browser dialog box, With Application > Docking Suite > Analyze Results can run in batches in read as a result, and in dialog box The upper right corner selects jobname.Clicking View can be in detail refering to these chemical structural formula and Abl and Bcr-AblT315IPair of kinases Map interlinking.
Result of giving a mark is as follows:
Compound number Abl(2GQG) AblT315I(3IK3)
Embodiment 1 6.7384 4.1356
Embodiment 2 7.7483 4.5895
Embodiment 3 7.0082 5.1886
Embodiment 4 7.0082 4.4911
Embodiment 5 7.8749 6.4907
Embodiment 6 5.4287 4.1189
Embodiment 7 9.9196 4.3985
Embodiment 8 8.0825 5.0091
Embodiment 9 9.6593 6.7628
Embodiment 10 11.0930 8.2173
Embodiment 11 6.0868 6.7832
Embodiment 12 7.3708 6.2569
Embodiment 13 10.1033 8.0148
Embodiment 14 7.0016 7.3846
Embodiment 15 9.6431 8.2938
Embodiment 16 6.9344 8.7044
The compound of marking the application as the result is shown is for Abl kinases and Bcr-AblT315IKinases has good binding ability, It is able to suppress Abl and Bcr-AblT315IActivity, and then efficiently solve T315I be mutated caused by resistance problems, can be used as anti- The novel B cr-Abl tyrosine kinase inhibitor of T315I mutation.
18 target protein kinase activity test result of embodiment
ADP-GloTMKinase assay
1 instrument and reagent
Workbench Purifying Equipment Co., Ltd., Suzhou
Biotek Instrument Ltd. of the microplate reader U.S.
Liquid-transfering gun U.S. ThermoFisher SCIENTIFIC
Shift its woods Bell's instrument manufacturing Co., Ltd of shaking table China Haimen
Complete white 384 orifice plate Germany Greiner
ADP-GloTMThe Beijing+ABL Kinase Enzyme System Promega() Bioisystech Co., Ltd
ADP-GloTM+ABLT315IThe Beijing Kinase Enzyme System Promega() Bioisystech Co., Ltd
The preparation of 2 kinase assay buffers
Configuring kinase buffer liquid and/or kinase assay reagent, kinase assay reagent to specifications should use immediately after preparing, or Person's packing is stored in -20 DEG C.The reagent prepared detects signal after freeze thawing several times and does not lose.
3 production ATP-ADP standard conversion curves
3.1 dilute reagent with 1X kinase reaction buffer (kit provides 5X kinase reaction buffer, need to dilute in advance) Ultra the Pure ATP and ADP that box provides, are made 1ml 1mM ATP and 500ul 1mM ADP(1ml 1mM ATP: taking 1 X kinase buffer liquid of 100ulATP, 900ul is made into；500ul 1mM ADP: 50ul ADP, 450ul 1X kinase buffer liquid are taken It is made into).
3.2 are added to 1ml 1mM ATP and 500ul 1mM ADP that the first step prepares by table 3 the EP pipe of 0.2 ml A1-A12 is mixed in hole, this is 1mM series.
3.3 are diluted to 25 μM of series in the hole B1-B12, for making the ATP-ADP transformation standard curve of ABL1.
3.4 are diluted to 5 μM of series in the hole C1-C12, for making ABLT315IATP-ADP transformation standard curve.
3.5 move the A1- of 5ul to 384 orifice plates from 25 μM matched, 5 μM of ATP+ADP series 0.2ml EP pipe B1-B12 A12,B1-B12；0.2ml EP pipe C1-C12 moves C1-C12, D1-D12 of the 5ul to 384 orifice plates.
3.6 incubation at room temperature 40min.
5ul ADP-Glo is added in the every hole of 3.7 384 orifice platesTMReagent terminates kinase reaction, while exhausting unconverted ATP leaves behind ADP.
3.8 press table 4, are incubated at room temperature certain time.
ADP is converted ATP by 3.9 addition 10ul kinase assay reagents, and introduces luciferase and fluorescein to detect ATP (10ul kinase assay reagent is added in the every hole 384 orifice plate A1-A12, B1-B12.
Be incubated at room temperature 30-60min, incubation time length depend on kinase reaction process used in ATP concentration (all for 30min), it is detected with Chemiluminescence Apparatus.
4 optimization kinase reaction conditions
The dosage that the amount of kinases is referred to specification uses (ABLT315IFor 1.4ng, ABL1 1ng).
5 utilize ADP-GloTMKinase assay screening compounds step
5.1 reagents prepare
Drug dilution: 8 1.5ml EP pipes are taken, No. 2-8 plus distilled water 600ul, No. 1 adds distilled water 1110.18ul, testization Close object 9.22ul, sesquialter dilution.
Drug concentration are as follows: 248 16 32 64 128 256 (μM ol/L)
DMSO dilution: 8 1.5ml EP pipes are taken, No. 2-8 plus distilled water 600ul, No. 1 adds distilled water 1110.18ul, DMSO 9.22ul, sesquialter dilution.
1X Buffer: taking 1.5ml EP to manage, and adds 800ul distilled water, and 5 X Buffer, 0.5ul DTT of 200ul is mixed It is even, (dosage can be first calculated before preparing).
62.5 μM of ATP: taking 1.5ml EP to manage, add 397.5ul 1X Buffer, 2.5ul Ultra Pure ATP, mixes It is even.
12.5 μM of ATP: taking 1.5ml EP to manage, add 200ul 1X Buffer, then plus 25 μM of ATP preparing take 50ul, mix It is even.
2.5ng/ul ABL1 protein kinase: taking 1.5ml EP to manage, add 117.0ul 1X Buffer, add 3.0ul ABL1, Active is mixed.
3.5ng/ul ABLT315IProtein kinase: it takes 1.5ml EP to manage, adds 115.8ul 1X Buffer, add 4.2ul ABLT315I, Active, mixing.
5.2 ABLT315IKinase assay
1. 0.2ml EP is taken to manage, it is denoted as 1., substrate is not added, add 18ul 3.5ng/ul ABLT315IProtein kinase, 18ul 1X Buffer, 36 12.5 μM of ul ATP are mixed, for use.
2. 0.2ml EP is taken to manage, it is denoted as 2., adds 90 ul 3.5ng/ul ABLLT315IProtein kinase, 90 ul substrates, 180 12.5 μM of ATP of ul are mixed, for use.
3. take 8 0.2ml EP pipe (No. 1 EP pipe), from low to high plus 2ul DMSO
8 0.2ml EP pipe (No. 2 EP pipes) is taken, from low to high plus 2ul DMSO
8 0.2ml EP pipe (3-6 EP pipe) is taken, from low to high plus 2ul compound (4 compounds)
3. No. 1 0.2ml EP pipe, every hole adds 8ul 0.2ml 1. EP pipe solution, and 2-6 0.2ml EP pipe, 2. every hole adds 8ul 0.2ml EP pipe solution mixes, goes to 384 orifice plates, every hole 5ul.
5. being incubated at room temperature 60min.
6. 5ul ADP-Glo is added in every holeTM, it is incubated for 40min.
7. 10ul kinase assay reagent is added in every hole, it is incubated for 30min, detection.
The protein kinase B cr-Abl of part of compoundsT315IIt is active as shown in the table:
ND:Not detected.
The test of 19 anti tumor activity in vitro of embodiment
Cell strain selects people's chronic myelogenous leukemia cell (K562), and the K562 cell of resistance to Imatinib (K562/R), human liver cancer is thin Born of the same parents (HepG-2), Non-small cell lung carcinoma cell (A549), Human normal hepatocyte (L02).
1) K562 cell, K562/R cell, HepG-2 cell, A549 cell and L02 cell are respectively with dual anti-and 10% containing 1% 1640 culture mediums of FBS are incubated at containing 5%CO2, in 37 DEG C of saturated humidity incubator, passage in 2 days is primary.K562/R cell is used It is based on containing 5%CO containing 1% dual anti-and 10%FBS, 4 μM of ol/L 1640 cultures2, in 37 DEG C of saturated humidity incubator, pass within 2-3 days In generation, is primary.
K562 cell, the K562/R cell for choosing logarithmic growth phase, being made into concentration with 1640 culture mediums containing 10%FBS is 4 ×104The cell suspension of/mL is inoculated into 96 well culture plates, and 100 μ L cell suspensions are added in every hole.In 5%CO2, 37 DEG C of saturation After continuing culture for 24 hours in humidified incubator, it is separately added into the 100 μ L of culture medium that compound concentration is 8,16,32,64,128 μM (3 secondary orifices of setting), continue after cultivating 48h, 20 μ L MTS are added, after being put into incubator culture 4h, with microplate reader in 490nm wave Strong point measures absorbance value (OD).It is repeated 3 times in parallel.
HepG-2 cell, A549 cell, the L02 cell for choosing logarithmic growth phase, are made into dense with the culture medium containing 10%FBS Degree is 5 × 104The cell suspension of/mL is inoculated into 96 well culture plates, and 100 μ L cell suspensions are added in every hole.In 5%CO2、37℃ Saturated humidity incubator in continue culture for 24 hours after, move abandon culture solution, then be separately added into compound concentration be 8,16,32,64, 3 secondary orifices are arranged in the 200 μ L(of culture medium of 128uM), continue after cultivating 48h, 20 μ L MTT are added, are put into incubator culture 4h Afterwards, culture medium is discarded, 150uL DMAO is added in every hole, sets low speed on shaking table, is protected from light shaking 10min and makes crystallization dissolution completely, uses Microplate reader measures absorbance value (OD) at 490nm wavelength.It is repeated 3 times in parallel.
Cell survival rate (cell viability) calculation formula is as follows: Cell viability=(ODDrug-ODBlank)/ (ODControl-ODBlank )×100%
Test result is as follows:
As seen from the above table, the compounds of this invention has CML cell cycling inhibiting and the K562 cell of resistance to Imatinib (K562/R) good Good inhibiting effect, i.e., equally have good inhibitory activity for the K562 cell with imatinib-resistant；It is right simultaneously There is lower toxicity in human normal liver cell L 02, while inhibiting cancer cell, can be avoided or reduce and is secondary to the poison of human body Effect.

Claims (10)

1.一种式I化合物或其药学上可接受的盐，其具有如下结构：1. A compound of formula I or a pharmaceutically acceptable salt thereof, having the structure: II 其中：R1各自独立地选自卤素、-OH、-NO2、-CN、C1-C6烷基、C1-C6烷氧基、C1-C6卤代烷基、C1-C6卤代烷氧基；wherein: R 1 is each independently selected from halogen, -OH, -NO 2 , -CN, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy; R2选自氢、C1-C6烷基、C1-C6烷氧基、C1-C6卤代烷基、C1-C6卤代烷氧基；R 2 is selected from hydrogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy; R3选自氢、-OH、-NO2、-CN、卤素、C1-C6烷基、C1-C6烷氧基、C1-C6卤代烷基、C1-C6卤代烷氧基、C6-C10芳基C1-C6烷基；R 3 is selected from hydrogen, -OH, -NO 2 , -CN, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy base, C 6 -C 10 aryl C 1 -C 6 alkyl; n选自0、1、2、3或4。n is selected from 0, 1, 2, 3 or 4. 2.如权利要求1所述的式I化合物或其药学上可接受的盐，R1各自独立地选自卤素、-OH、C1-C4烷基、C1-C4烷氧基、C1-C4卤代烷基，优选为甲基、氯、氟、羟基、三氟甲基；n选自0、1或2，优选为0或1。2. The compound of formula I according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 1 is each independently selected from halogen, -OH, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, preferably methyl, chlorine, fluorine, hydroxy, trifluoromethyl; n is selected from 0, 1 or 2, preferably 0 or 1. 3.如权利要求1或2所述的式I化合物或其药学上可接受的盐，R2选自氢、C1-C4烷基、C1-C4卤代烷基，优选为甲基、乙基、三氟甲基；R3选自氢、-OH、卤素、C1-C4烷基、C1-C6烷氧基、C1-C4卤代烷基、C1-C4卤代烷氧基、苄基，优选为氢、苄基。3. The compound of formula I as claimed in claim 1 or 2 or a pharmaceutically acceptable salt thereof, R 2 is selected from hydrogen, C1-C4 alkyl, C1-C4 haloalkyl, preferably methyl, ethyl, tri Fluoromethyl; R 3 is selected from hydrogen, -OH, halogen, C 1 -C 4 alkyl, C 1 -C 6 alkoxy, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, benzyl group, preferably hydrogen and benzyl. 4.如权利要求1或2所述的式I化合物，其选自如下化合物：4. The compound of formula I according to claim 1 or 2, which is selected from the group consisting of the following compounds: 。 . 5.一种制备如权利要求1所述的式I化合物的方法，其反应路线如下：5. a method for preparing the compound of formula I as claimed in claim 1, its reaction scheme is as follows: ； ; 其中，R1、R2、R3和n的定义如权利要求1所述，R4选自C1-C6烷基或C1-C6卤代的烷基。Wherein, the definitions of R 1 , R 2 , R 3 and n are as described in claim 1 , and R 4 is selected from C 1 -C 6 alkyl or C 1 -C 6 halogenated alkyl. 6.如权利要求5所述的制备方法，其特征在于包括如下反应步骤：6. preparation method as claimed in claim 5 is characterized in that comprising following reaction step: 步骤一：向反应器中加入硫氰酸铵和丙酮，搅拌均匀，然后滴加苯甲酰氯, 溶液由澄清变为白色浑浊液，加热至回流，分批加入间氨基苯甲酸，待反应完毕后，冷却，过滤，将所得固体干燥，得3-（3-苯甲酰基硫脲基）苯甲酸（即中间体1）；Step 1: Add ammonium thiocyanate and acetone into the reactor, stir evenly, then add benzoyl chloride dropwise, the solution changes from clear to white turbid liquid, heat to reflux, add m-aminobenzoic acid in batches, after the reaction is completed , cooled, filtered, and the resulting solid was dried to obtain 3-(3-benzoylthioureido)benzoic acid (ie, intermediate 1); 步骤二：向反应瓶中加入3-（3-苯甲酰基硫脲基）苯甲酸和碱性水溶液，使pH=13，搅拌，加热回流，直至反应完毕，冷却至室温，加入稀盐酸，将pH调到2，静置24 h，析出固体，过滤，将固体干燥，得3-羧基苯基硫脲（即中间体2）；Step 2: Add 3-(3-benzoylthioureido)benzoic acid and alkaline aqueous solution to the reaction flask to make pH=13, stir, heat to reflux until the reaction is completed, cool to room temperature, add dilute hydrochloric acid, The pH was adjusted to 2, left standing for 24 h, the solid was precipitated, filtered, and the solid was dried to obtain 3-carboxyphenylthiourea (ie, intermediate 2); 步骤三：向反应瓶中加入3-羧基苯基硫脲、取代的2-Br-1-苯基烷基酮和冰醋酸，搅拌均匀，加热至回流，反应完毕后，趁热除去反应瓶中的不溶固体，旋蒸部分溶剂，放入通风厨中常温冷却24 h，析出固体，过滤，将所得固体干燥，得中间体噻唑氨基苯甲酸衍生物（3）；Step 3: Add 3-carboxyphenylthiourea, substituted 2-Br-1-phenylalkyl ketone and glacial acetic acid into the reaction flask, stir evenly, heat to reflux, and remove the reaction flask while hot after the reaction is completed. The insoluble solid was evaporated by rotary evaporation, put into a fume hood and cooled at room temperature for 24 h, the solid was precipitated, filtered, and the obtained solid was dried to obtain the intermediate thiazole aminobenzoic acid derivative (3); 步骤四：在冰浴条件下加入中间体噻唑氨基苯甲酸衍生物、EDCI、HOBT和无水乙醇至反应瓶中，反应2-4 h，加入盐酸盐、DIPEA、DMAP和DMF继续冰浴反应半小时，之后改为室温反应，直至反应完毕，再边搅拌边缓慢加入冰水，直到溶液由澄清变为浑浊，室温搅拌0.5-1.5 h，再放入冰箱析出白色固体，过滤，将所得固体干燥，得中间体4;Step 4: Add intermediate thiazole aminobenzoic acid derivative, EDCI, HOBT and absolute ethanol to the reaction flask under ice bath condition, react for 2-4 h, add The hydrochloride, DIPEA, DMAP and DMF continued to react in ice bath for half an hour, then changed to room temperature until the reaction was completed, and then slowly added ice water while stirring until the solution changed from clear to turbid, and stirred at room temperature for 0.5-1.5 h, Then put into the refrigerator to separate out white solid, filter, and dry the gained solid to obtain Intermediate 4; 步骤五：向反应瓶中加入中间体4、无水乙醇和蒸馏水，用稀NaOH调节pH至为11-13，37℃搅拌，反应过程监控pH，低于10时及时调为11-13；TLC 监测反应进程，反应完毕后，过滤，弃滤渣，滤液用稀HCl调pH为1-4，放入冰箱析出固体，过滤，干燥得式I化合物。Step 5: Add intermediate 4, absolute ethanol and distilled water to the reaction flask, adjust the pH to 11-13 with dilute NaOH, stir at 37°C, monitor the pH during the reaction, and adjust the pH to 11-13 in time when it is lower than 10; TLC Monitor the reaction progress, after the reaction is completed, filter, discard the filter residue, adjust the pH of the filtrate to 1-4 with dilute HCl, put into a refrigerator to precipitate solids, filter, and dry to obtain the compound of formula I. 7.如权利要求6所述的制备方法，其特征在于：7. preparation method as claimed in claim 6 is characterized in that: 步骤一的间氨基苯甲酸、硫氰酸铵和苯甲酰氯的摩尔比为1 : 1-1.5 : 1-1.5，优选为1 : 1.2 : 1.3；The mol ratio of m-aminobenzoic acid, ammonium thiocyanate and benzoyl chloride of step 1 is 1: 1-1.5: 1-1.5, preferably 1: 1.2: 1.3; 步骤二碱性水溶液为10% NaOH水溶液，稀盐酸浓度为4 mol/L；The alkaline aqueous solution of step two is 10% NaOH aqueous solution, and the dilute hydrochloric acid concentration is 4 mol/L; 步骤三的3-羧基苯基硫脲和取代的2-Br-1-苯基烷基酮的摩尔比为1 : 1-1.2；优选为1 : 1；The mol ratio of the 3-carboxyphenyl thiourea of step 3 and the substituted 2-Br-1-phenyl alkyl ketone is 1: 1-1.2; preferably 1: 1; 步骤五中反应过程中的pH优选为12，后处理过程中的pH优选为2-3，稀NaOH为5%-30%的NaOH水溶液，稀HCl为5%-15%的盐酸溶液。In step 5, the pH in the reaction process is preferably 12, the pH in the post-treatment process is preferably 2-3, the dilute NaOH is a 5%-30% aqueous NaOH solution, and the dilute HCl is a 5%-15% hydrochloric acid solution. 8.一种药物组合物，其包含权利要求1-5中任一项的式I所示化合物或其药学上可接受的盐，以及药学上可接受的载体、赋形剂。8. a pharmaceutical composition, it comprises the compound shown in formula I in any one of claim 1-5 or its pharmaceutically acceptable salt, and pharmaceutically acceptable carrier, excipient. 9.权利要求1-5中任一项所述的化合物或权利要求8所述的药物组合物在制备治疗癌症的药物中的用途，优选地，所述癌症是以Bcr-Abl酪氨酸激酶为靶点的癌症，尤其是针对T315I 突变的 Bcr-Abl酪氨酸激酶为靶点的癌症。9. the purposes of the compound described in any one of claim 1-5 or the pharmaceutical composition described in claim 8 in the preparation of the medicine for the treatment of cancer, preferably, described cancer is with Bcr-Abl tyrosine kinase Targeted cancers, especially those targeting the T315I-mutated Bcr-Abl tyrosine kinase. 10.如权利要求9所述的用途，其特征在于，所述癌症选自人慢性粒细胞白血病、肝癌、非小细胞肺癌，优选为人慢性髓系白血病、K562耐伊马替尼细胞株。10. The use according to claim 9, wherein the cancer is selected from human chronic myeloid leukemia, liver cancer, and non-small cell lung cancer, preferably human chronic myeloid leukemia and K562 imatinib-resistant cell line.
CN201811209798.5A 2018-10-17 2018-10-17 Thiazoleaminobenzamide acetic acid derivatives and uses thereof Active CN109320473B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811209798.5A CN109320473B (en) 2018-10-17 2018-10-17 Thiazoleaminobenzamide acetic acid derivatives and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811209798.5A CN109320473B (en) 2018-10-17 2018-10-17 Thiazoleaminobenzamide acetic acid derivatives and uses thereof

Publications (2)

Publication Number Publication Date
CN109320473A true CN109320473A (en) 2019-02-12
CN109320473B CN109320473B (en) 2022-11-22

Family

ID=65262174

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811209798.5A Active CN109320473B (en) 2018-10-17 2018-10-17 Thiazoleaminobenzamide acetic acid derivatives and uses thereof

Country Status (1)

Country Link
CN (1) CN109320473B (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111875558A (en) * 2020-08-21 2020-11-03 深圳市第二人民医院(深圳市转化医学研究院) Thiazolidine derivative and application thereof in depression resistance
CN111909111A (en) * 2020-08-21 2020-11-10 深圳市第二人民医院(深圳市转化医学研究院) A kind of 5-alkyl thiazolamine derivative and its antidepressant use
WO2021178488A1 (en) * 2020-03-03 2021-09-10 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
US12030875B2 (en) 2018-09-07 2024-07-09 PIC Therapeutics, Inc. EIF4E inhibitors and uses thereof
US12157732B2 (en) 2021-08-25 2024-12-03 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1829513A (en) * 2003-06-03 2006-09-06 诺瓦提斯公司 5-membered heterocycle-based p-38 inhibitors
CN101217954A (en) * 2005-04-04 2008-07-09 Ab科学公司 Substituted oxazole derivatives and their use as tyrosine kinase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1829513A (en) * 2003-06-03 2006-09-06 诺瓦提斯公司 5-membered heterocycle-based p-38 inhibitors
CN101217954A (en) * 2005-04-04 2008-07-09 Ab科学公司 Substituted oxazole derivatives and their use as tyrosine kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DEPING WANG ET AL.: "Hybrid compounds as new Bcr/Abl inhibitors", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12030875B2 (en) 2018-09-07 2024-07-09 PIC Therapeutics, Inc. EIF4E inhibitors and uses thereof
WO2021178488A1 (en) * 2020-03-03 2021-09-10 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
CN115515685A (en) * 2020-03-03 2022-12-23 皮克医疗公司 EIF4E inhibitor and application thereof
US11753403B2 (en) 2020-03-03 2023-09-12 PIC Therapeutics, Inc. EIF4E inhibitors and uses thereof
US12157731B2 (en) 2020-03-03 2024-12-03 PIC Therapeutics, Inc. EIF4E inhibitors and uses thereof
CN111875558A (en) * 2020-08-21 2020-11-03 深圳市第二人民医院(深圳市转化医学研究院) Thiazolidine derivative and application thereof in depression resistance
CN111909111A (en) * 2020-08-21 2020-11-10 深圳市第二人民医院(深圳市转化医学研究院) A kind of 5-alkyl thiazolamine derivative and its antidepressant use
US12157732B2 (en) 2021-08-25 2024-12-03 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof

Also Published As

Publication number Publication date
CN109320473B (en) 2022-11-22

Similar Documents

Publication Publication Date Title
CN109320473A (en) Thiazole aminobenzamide acetic acid derivatives and their uses
CN107176954B (en) A kind of pharmaceutical salts and its crystal form, preparation method and application of EGFR inhibitor
CN109456279A (en) Thiazoleamino benzamide acetic ester derivative and application thereof
EP2896620A1 (en) Alkynyl heteroaromatic ring compound and application thereof
CN107929276A (en) A kind of taxol and CDKS kinase inhibitor drug combination compositions
CN108125944A (en) A kind of taxol and CDKS kinase inhibitor antineoplastic combination pharmaceutical compositions
CN105884712A (en) Compound capable of inhibiting activity of NEDD8 kinase as well as preparation method and pharmaceutical application of compound
WO2014040242A1 (en) 3-chloro- and 3-methoxy-n-methyl-2-pyridine carboxamide compound and application thereof as anticancer medicament
CN107406448A (en) ((base of 4 methyl, the 2 oxypiperazin 1) methyl) 3 of N (base of 5 cyano group 4 ((2 methoxyethyl) amino) pyridine 2) 7 formoxyl 6; the particle of 4 dihydro 1,8 naphthyridines 1 (2H) formamide
JP2023504866A (en) Fluorine-containing heterocyclic derivative having macrocyclic structure and use thereof
CN109232467A (en) Thiazoleamino benzoic acid derivative and application thereof
EP3181554B1 (en) Quinazoline derivative
CN112778282B (en) Pyrimidine micromolecule compound and application thereof
CN108623511A (en) A kind of indole amides class compound can be used for treating cancer
CN107200715A (en) Quinazoline derivant and its application in antineoplastic is prepared
JP7311918B2 (en) Novel pan-RAF kinase inhibitor and use thereof
WO2024235013A1 (en) Indazolyl-containing hydroxamic acid derivative and use thereof
WO2011143864A1 (en) Anticancer compounds and preparation methods thereof
CN108530337A (en) A kind of alternative indole amides class compound for inhibiting stomach cancer cell
CN101896460B (en) Proteinase inhibitors useful for treating cancer
CN111675647B (en) 2-indolone PAK1 inhibitor and application thereof in antitumor drugs
CN108912035B (en) Indole amide compound with anti-tumor activity
CN103588766B (en) Containing 3-(1H-3-the indyl)-1H-pyrazole derivatives and its preparation method and application of 1,3,4-oxadiazoles
CN102942561A (en) 4-amino quinazoline heterocyclic compound and purpose of 4-amino quinazoline heterocyclic compound
CN103221415A (en) Oxazolo [5, 4 -] pyridin-5-yl compounds and their use for the treatment of cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant